KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.

Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chao Ji, Jing Sun, Yanping Qiu, Bo Chen, Jianzhong Zhang

Int J Dermatol 65(6) 1185-1194

PMID41272415
PMCIDPMC13161509
DOI10.1111/ijd.70175
发表日期2025-11-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Elderly patients with moderate-to-severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti-interleukin-4 receptor α subunit (IL-4Rα) monoclonal antibody, in different age subgroups. METHODS: Eligible adults were randomized to receive subcutaneous stapokibart 300 mg every 2 weeks (Q2W; loading dose 600 mg) or placebo for 16 weeks. All patients subsequently received stapokibart 300 mg Q2W for 36 weeks. In this post hoc analysis, patients were classified as elderly (aged ≥ 60 years, n = 93) and non-elderly patients (aged 18 and < 60 years, n = 407). Main efficacy outcomes included ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI-75), Investigator's Global Assessment (IGA) 0/1, and ≥ 4-point reduction in weekly average of daily peak pruritus Numerical Rating Scale (PP-NRS) score. RESULTS: In elderly patients at Week 16, response rates for stapokibart versus placebo were 56.0% vs. 14.0% for EASI-75 (p < 0.0001), 40.0% vs. 7.0% for IGA 0/1 (p = 0.0003), and 32.0% vs. 7.0% for ≥ 4-point reduction in weekly average of daily PP-NRS (p = 0.0023). In non-elderly patients, corresponding response rates were 69.7% vs. 28.3%, 45.3% vs. 18.0%, and 36.8% vs. 12.7%, respectively (all p < 0.0001). Within both age subgroups, progressive improvements across all efficacy measures were observed during the maintenance treatment period. The incidence of treatment-emergent adverse events was similar between stapokibart and placebo groups during the 16-week treatment period, regardless of age. CONCLUSION: Stapokibart was effective and had a favorable safety profile in elderly patients with moderate-to-severe AD.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

FIGURE 1

FIGURE 1 Response rates of (A) EASI‐75, (B) EASI‐90, (C) IGA 0/1, and (D) PP‐NRS score in elderly patients ( n = 93) and non‐elderly patients ( n = 406) during weeks 0–52. E, elderly; EASI‐75/90, ≥ 75%/90% improvement in Eczema Area and Severity Index score; IGA 0/1, Investigator's Global Assessment score of 0 or 1; NE, non‐elderly; PBO, placebo; PP‐NRS, peak pruritus Numerical Rating Scale.

A

EASI-75

FIGURE 1 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

EASI-90

FIGURE 1 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 3:extreme jump
查看结果
C

IGA 0/1

FIGURE 1 · Panel C

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel C 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

PP-NRS

FIGURE 1 · Panel D

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel D 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 2FIGURE 2 Percentage changes from baseline in (A) EASI, (B) PP‐NRS, (C) DLQI, and (D) POEM scores in elderly patients ( n = 93) and non‐elderly patients ( n = 406) over 52 weeks. DLQI, Dermatology Life Quality Index; E, elderly; EASI, Eczema Area and Severity Index; NE, non‐elderly; PBO, placebo; POEM, Patient‐Oriented Eczema Measure; PP‐NRS, peak pruritus Numerical Rating Scale; SE, standard error.
非 KM Figure